Abstract
Background and aim
The most common malignancy affecting the liver is metastasis from a wide variety of tumors, particularly those of gastrointestinal origin. Successful surgical removal of a solitary liver metastasis may significantly extend survival and optimal preoperative assessment in this regard is a mandatory prerequisite for proper patient selection. The addition of positron emission tomography/computed tomography (PET/CT) to other more conventional imaging procedures (e.g., ultrasound (US), CT, and magnetic resonance) has the potential to greatly improve the selection process by the combination of high-resolution anatomy afforded by CT directly combined with the functional scintigraphic map of intra- and extrahepatic lesions depicted by 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-PET. In this study, we assess the additional value of PET/CT in the management strategy of patients with solitary liver metastasis from colorectal and other cancers identified by conventional imaging methods.
Methods
We evaluated 43 consecutive patients (17 males, 26 females, mean age 53 ± 6 years) with known solitary liver metastasis. This sample consisted of 18 patients with colorectal cancer, 15 with nonsmall cell lung cancer, six with breast carcinoma, and four ovarian cancers. In addition to contrast-enhanced CT and US, all patients were studied with FDG-PET/CT before surgery. PET/CT was performed within 3 weeks of the initial diagnosis and the scans were read by two experienced radiologists/nuclear medicine specialists blinded to the clinical data. A final diagnosis was obtained at surgery in 31 patients, by fine needle biopsy in five, and long-term clinical, biochemical, and follow-up imaging in seven patients.
Results
In 12 out of 43 patients (28%), PET/CT resulted in restaging disease and a change in therapy. Twenty-two of 31 patients with confirmed solitary liver lesions (71%) were disease-free, eight of 31 (26%) developed a new recurrence, and one of 31 (3%) died from disease progression over a 17 ± 6-month follow-up interval. Nine of 12 patients (75%) with multiple metastases demonstrated by FDG-PET/CT were alive with disease and three of 12 (25%) deceased due to disease progression (p < 0.01) over a 17 ± 6-month follow-up interval.
Conclusion
The addition of FDG-PET/CT to the routine assessment of patients with liver metastasis has a significant impact on disease staging and selection of suitable candidates for solitary liver metastasis resection and outcome.
This is a preview of subscription content, log in via an institution to check access.
References
Arciero CA, Sigurdson ER (2008) Diagnosis and treatment of metastatic disease to the liver. Semin Oncol 35:147–159
Selzner M, Hany T, Wildbrett P, McCormack L, Kadry Z, Clavien PA (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240:135–139
Kosharuya M, Jagad RB, Kawamoto J, Papastratis P, Kefalourous H, Porfiris T et al (2007) An update and our experience with metastatic liver disease. Hepatogastroenterology 54:2232–2239
Huguet El, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV (2007) F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology 54:1667–1671
Figueras J, Farran L, Benasco C, Ribas Y, Ramos E, Borobia FG et al (1997) Vascular occlusion in hepatic resection in cirrhotic rat livers: an experimental study in rats. Liver Transplant Surg 3:617–623
Fong Y, Fortner J, Sun RL Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321
Millikan KW, Staren ED, Doolas A (1997) Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 77:27–48
Tan MC, Castaldo ET, Gao F, Chari RS, Linehan DC, Wright JK et al (2008) A prognostic system applicable to patients with respectable liver metastasis from colorectal carcinoma staged by positron emission tomography with 18F-FDG: role of primary tumor variables. J Am Coll Surg 20:857–868
Bipat S, Leewen MS, Comans EFI, Pijl ME, Bossuyt PM, Zwinderman AH et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. Radiology 237:123–131
Kinkerl K, Lu Y, Warren BM, RS TRS (2002) Detection of hepatic metastases from cancer of the gastrointestinal tract by using non-invasive method (Us, CT, MRI, PET): a meta-analysis. Radiology 224:748–756
Ward J, Robinson PJ, Guthrie JA, Downing S, Wilson D, Lodge JP (2005) Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 237:170–180
Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ (2005) The impact of FDG-PET in the management of colorectal liver metastasis. Cancer 104:2658–2670
Desai DC, Zervos EE, Burak AMW, Jr WE, Mantil J, Martin EW Jr (2003) Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 10:59–64
Rydzewski B, Dehdashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA (2002) Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG-PET. AJR Am J Roentgenol 178:353–358
Kong G, Jackson C, Koh M, Lewington V, Sharma B, Brown G et al (2008) The use of 18F-FDG-PET/CT in colorectal liver metastases- comparison with CT and liver MRI. Eur Nucl Med Mol Imaging 35:1323–1329
Wiering B, Krabbe PFM, Dekker HM, Oyen WJG, Ruers TJM (2007) The role of FDG-PET in selection of patients with colorectal liver metastases. Ann Surg Oncol 14:771–779
Sorensen M, Mortensen FV, Hoyer M, Vilstrup H, Keiding S (2007) FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study. Scand J Surg 96:209–213
Chua SC, Ashley MG, Irfan K, Menez L, Svetislav G, Du Y et al (2007) The impact of 18F-FDG-PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 34:1906–1914
Sun L, Wu H, Guan YS (2007) Positron emission tomography/computed tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 13:2775–2783
Hicks RJ, Ware RE, Lau EF (2006) PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging 6:S52–S62
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grassetto, G., Fornasiero, A., Bonciarelli, G. et al. Additional Value of FDG-PET/CT in Management of “Solitary” Liver Metastases: Preliminary Results of a Prospective Multicenter Study. Mol Imaging Biol 12, 139–144 (2010). https://doi.org/10.1007/s11307-009-0249-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-009-0249-5